Table 1.
Baseline patients' characteristics (N = 70)
| Characteristics | n (%) |
|---|---|
| Demographics | |
| Gender | |
| Male | 45 (64.3) |
| Female | 25 (35.7) |
| Histology | |
| Clear cell carcinoma | 67 (95.7) |
| Clear cell carcinoma component | 3 (4.3) |
| Fuhrman grade (primary kidney tumor) | |
| 2 | 9 (12.9) |
| 3 | 33 (47.1) |
| 4 | 18 (25.7) |
| Unknown | 10 (14.3) |
| Sarcomatoid features | |
| Present | 10 (14.3) |
| Absent | 28 (40.0) |
| Unknown | 32 (45.7) |
| Prior nephrectomy | |
| Yes | 69 (98.6) |
| No | 1 (1.4) |
| Prior targeted therapies | |
| High dose—interleukin 2 | |
| Yes | 23 (32.9) |
| No | 47 (67.1) |
| Number of prior antiangiogenic therapiesa | |
| 0 | 18 (25.7) |
| 1 | 39 (55.7) |
| 2–3 | 13 (18.6) |
| Prior mTOR inhibitor | |
| Yes | 7 (10.0) |
| No | 63 (90.0) |
| Type of PD-1 inhibitor regimen | |
| PD-1 inhibitor monotherapy | 32 (45.7) |
| aPD-1 in combination with VEGFR-TKI | 21 (30.0) |
| aPD-1 in combination CTLA-4 inhibitor | 17 (24.3) |
aSunitinib, pazopanib, sorafenib, axitinib, bevacizumab, tivozanib, ziv-aflibercept; combination of sunitinib–bevacizumab.
mTOR: mammalian target of rapamycin; PD-1: programmed cell death 1; aPD-1: anti-PD-1 antibody; VEGFR-TKI: vascular endothelial growth factor receptor–tyrosine kinase inhibitors; CTLA: cytotoxic leukocyte antigen 4.